Sessa Capital’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
Other funds holding SABS
Sessa Capital's SABS Position: Q3 2026 in Review
Sessa Capital held its SAB Biotherapeutics (SABS) position steady in Q3 2026 at 2,198,457 shares worth $6.97M. The position accounts for 0.1% of the portfolio, ranked #27.
Sessa Capital first reported a position in SABS in Q4 2023 and has held it in 12 quarters since. The position peaked at $8.57M in Q2 2026. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.
- Sessa Capital held 2,198,457 shares of SAB Biotherapeutics worth $6.97M as of Q3 2026.
- Sessa Capital left its SAB Biotherapeutics share count unchanged in Q3 2026.
- SAB Biotherapeutics made up 0.1% of Sessa Capital's portfolio in Q3 2026, its #27 holding.
- Sessa Capital first reported a position in SAB Biotherapeutics in Q4 2023 and has held it in 12 quarters since.
- Sessa Capital's SAB Biotherapeutics position peaked at $8.57M in Q2 2026.
- 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.
Based on Sessa Capital's 13F filing for Q3 2026, filed 16 Nov 2026.